Evaluation of maternal infusion therapy during pregnancy for fetal development

Dóra Petik, E. Puhó, E. Czeizel

Research output: Contribution to journalArticle

Abstract

The aim of this project was to study the possible association between maternal infusion treatments during pregnancy and variables of fetal development as well as the occurrence of congenital abnormalities (CA) in a casecontrol design. The large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities (HCCSCA) was evaluated based on the medically recorded infusion treatment during pregnancy. Of 22,843 case pregnant women who had newborns or fetuses with congenital abnormalities, 112 (0.5%), while of 38,151 control pregnant women who had newborn infants without any defects, 262 (0.7%), had infusion treatment during pregnancy. Infusion treatment was more frequent in the control group than in the case group with congenital abnormalities (adjusted POR with 945 95% CI: 0.7, 0.6-0.9) and there was no higher rate of maternal infusion treatments in any congenital abnormality group. Mean gestational age was shorter and mean birth weight was smaller in control newborn infants without CA born to mothers with infusion treatment during pregnancy than in the babies of mothers without infusion treatment. The prevalence of mild intrauterine growth retardation was more frequent in the fetuses of pregnant women with hyperemesis gravidarum treated with infusion. The results of the study suggest that infusion treatment of pregnant women did not associate with a higher risk of congenital abnormalities. In addition, the intravenous infusion of drugs has some, but limited efficacy to prevent the adverse effects of hyperemesis gravidarum and threatened preterm delivery. Copyright

Original languageEnglish
Pages (from-to)137-142
Number of pages6
JournalInternational Journal of Medical Sciences
Volume2
Issue number4
Publication statusPublished - 2005

Fingerprint

Fetal Development
Mothers
Pregnancy
Pregnant Women
Hyperemesis Gravidarum
Newborn Infant
Therapeutics
Fetus
Fetal Growth Retardation
Intravenous Infusions
Birth Weight
Gestational Age
Control Groups
Pharmaceutical Preparations
Population

Keywords

  • Congenital abnormalities
  • Infusion treatment
  • Intrauterine growth retardation
  • Preterm birth
  • Underlying pregnancy complications

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Evaluation of maternal infusion therapy during pregnancy for fetal development. / Petik, Dóra; Puhó, E.; Czeizel, E.

In: International Journal of Medical Sciences, Vol. 2, No. 4, 2005, p. 137-142.

Research output: Contribution to journalArticle

@article{577ecd0778ec4a10991ddd312d908d5f,
title = "Evaluation of maternal infusion therapy during pregnancy for fetal development",
abstract = "The aim of this project was to study the possible association between maternal infusion treatments during pregnancy and variables of fetal development as well as the occurrence of congenital abnormalities (CA) in a casecontrol design. The large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities (HCCSCA) was evaluated based on the medically recorded infusion treatment during pregnancy. Of 22,843 case pregnant women who had newborns or fetuses with congenital abnormalities, 112 (0.5{\%}), while of 38,151 control pregnant women who had newborn infants without any defects, 262 (0.7{\%}), had infusion treatment during pregnancy. Infusion treatment was more frequent in the control group than in the case group with congenital abnormalities (adjusted POR with 945 95{\%} CI: 0.7, 0.6-0.9) and there was no higher rate of maternal infusion treatments in any congenital abnormality group. Mean gestational age was shorter and mean birth weight was smaller in control newborn infants without CA born to mothers with infusion treatment during pregnancy than in the babies of mothers without infusion treatment. The prevalence of mild intrauterine growth retardation was more frequent in the fetuses of pregnant women with hyperemesis gravidarum treated with infusion. The results of the study suggest that infusion treatment of pregnant women did not associate with a higher risk of congenital abnormalities. In addition, the intravenous infusion of drugs has some, but limited efficacy to prevent the adverse effects of hyperemesis gravidarum and threatened preterm delivery. Copyright",
keywords = "Congenital abnormalities, Infusion treatment, Intrauterine growth retardation, Preterm birth, Underlying pregnancy complications",
author = "D{\'o}ra Petik and E. Puh{\'o} and E. Czeizel",
year = "2005",
language = "English",
volume = "2",
pages = "137--142",
journal = "International Journal of Medical Sciences",
issn = "1449-1907",
publisher = "Ivyspring International Publisher",
number = "4",

}

TY - JOUR

T1 - Evaluation of maternal infusion therapy during pregnancy for fetal development

AU - Petik, Dóra

AU - Puhó, E.

AU - Czeizel, E.

PY - 2005

Y1 - 2005

N2 - The aim of this project was to study the possible association between maternal infusion treatments during pregnancy and variables of fetal development as well as the occurrence of congenital abnormalities (CA) in a casecontrol design. The large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities (HCCSCA) was evaluated based on the medically recorded infusion treatment during pregnancy. Of 22,843 case pregnant women who had newborns or fetuses with congenital abnormalities, 112 (0.5%), while of 38,151 control pregnant women who had newborn infants without any defects, 262 (0.7%), had infusion treatment during pregnancy. Infusion treatment was more frequent in the control group than in the case group with congenital abnormalities (adjusted POR with 945 95% CI: 0.7, 0.6-0.9) and there was no higher rate of maternal infusion treatments in any congenital abnormality group. Mean gestational age was shorter and mean birth weight was smaller in control newborn infants without CA born to mothers with infusion treatment during pregnancy than in the babies of mothers without infusion treatment. The prevalence of mild intrauterine growth retardation was more frequent in the fetuses of pregnant women with hyperemesis gravidarum treated with infusion. The results of the study suggest that infusion treatment of pregnant women did not associate with a higher risk of congenital abnormalities. In addition, the intravenous infusion of drugs has some, but limited efficacy to prevent the adverse effects of hyperemesis gravidarum and threatened preterm delivery. Copyright

AB - The aim of this project was to study the possible association between maternal infusion treatments during pregnancy and variables of fetal development as well as the occurrence of congenital abnormalities (CA) in a casecontrol design. The large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities (HCCSCA) was evaluated based on the medically recorded infusion treatment during pregnancy. Of 22,843 case pregnant women who had newborns or fetuses with congenital abnormalities, 112 (0.5%), while of 38,151 control pregnant women who had newborn infants without any defects, 262 (0.7%), had infusion treatment during pregnancy. Infusion treatment was more frequent in the control group than in the case group with congenital abnormalities (adjusted POR with 945 95% CI: 0.7, 0.6-0.9) and there was no higher rate of maternal infusion treatments in any congenital abnormality group. Mean gestational age was shorter and mean birth weight was smaller in control newborn infants without CA born to mothers with infusion treatment during pregnancy than in the babies of mothers without infusion treatment. The prevalence of mild intrauterine growth retardation was more frequent in the fetuses of pregnant women with hyperemesis gravidarum treated with infusion. The results of the study suggest that infusion treatment of pregnant women did not associate with a higher risk of congenital abnormalities. In addition, the intravenous infusion of drugs has some, but limited efficacy to prevent the adverse effects of hyperemesis gravidarum and threatened preterm delivery. Copyright

KW - Congenital abnormalities

KW - Infusion treatment

KW - Intrauterine growth retardation

KW - Preterm birth

KW - Underlying pregnancy complications

UR - http://www.scopus.com/inward/record.url?scp=25644451985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25644451985&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 137

EP - 142

JO - International Journal of Medical Sciences

JF - International Journal of Medical Sciences

SN - 1449-1907

IS - 4

ER -